VA deploys chatbot to guide vets through the pandemic 24/7

Dave Pearson | | Health Exec | Precision Medicine
Chatbot

Working with a software consultancy that operates in 14 countries, the Department of Veterans Affairs has launched an interactive digital assistant to take U.S. veterans’ questions on COVID-19 and related concerns.

The consultancy, Chicago-headquartered ThoughtWorks, says the interactive chatbot system was built and put to work in less than a month. It uses the CDC’s COVID-19 symptom checker and Microsoft’s Health Bot Service.

Along with anytime helps on self-diagnosis, the virtual aide conversationally dispenses tips to vets 24/7 on things like stimulus payments, telehealth, scheduling and prescription refills.

Charles Worthington, the VA’s chief technology officer, says the COVID chatbot is “a great example of the VA’s commitment to using new technologies to improve our services.”

Dave Pearson
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
AMA agrees to help after initial request for an independent cardiovascular board was denied

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

Cardiovascular Business
Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

Cardiovascular Business
AMA House of Delegates helps cardiology groups influence healthcare policies

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.